A 6-month, open-label study of memantine
β
Janine Diehl-Schmid; Hans FΓΆrstl; Robert Perneczky; Corina Pohl; Alexander Kurz
π
Article
π
2008
π
John Wiley and Sons
π
English
β 72 KB
## Abstract ## Objective To evaluate safety and effects on cognition and behavior of memantine 20βmg/day in the treatment of patients with frontotemporal dementia (FTD). ## Methods This was a singleβcenter, 6βmonth, open, uncontrolled study. Sixteen outpatients with a diagnosis of FTD were enrol